PHT-427
≥98%
- Product Code: 225105
CAS:
1191951-57-1
| Molecular Weight: | 409.61 g./mol | Molecular Formula: | C₂₀H₃₁N₃O₂S₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
PHT-427 is primarily investigated for its potential in cancer therapy due to its ability to inhibit key signaling pathways involved in tumor growth and survival. It targets the pleckstrin homology (PH) domains of proteins such as AKT and PDK1, which are critical in the PI3K/AKT/mTOR pathway—a pathway frequently dysregulated in many cancers. By blocking these domains, PHT-427 disrupts the activation and localization of AKT, leading to reduced cell proliferation, increased apoptosis, and suppression of tumor progression in preclinical models.
It has shown activity in various cancer types, including breast, prostate, and lung cancers, especially in tumors with hyperactive PI3K pathway signaling. Additionally, PHT-427 may enhance the effects of other anticancer agents, making it a candidate for combination therapies. Its unique mechanism of action—targeting PH domains rather than kinase activity—offers a novel approach to overcoming resistance seen with traditional kinase inhibitors. Research remains largely in the preclinical stage, but it holds promise as a targeted therapeutic agent in oncology.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 10mg | 10-20 days | ฿3,390.00 |
+
-
|
| 50mg | 10-20 days | ฿12,100.00 |
+
-
|
PHT-427
PHT-427 is primarily investigated for its potential in cancer therapy due to its ability to inhibit key signaling pathways involved in tumor growth and survival. It targets the pleckstrin homology (PH) domains of proteins such as AKT and PDK1, which are critical in the PI3K/AKT/mTOR pathway—a pathway frequently dysregulated in many cancers. By blocking these domains, PHT-427 disrupts the activation and localization of AKT, leading to reduced cell proliferation, increased apoptosis, and suppression of tumor progression in preclinical models.
It has shown activity in various cancer types, including breast, prostate, and lung cancers, especially in tumors with hyperactive PI3K pathway signaling. Additionally, PHT-427 may enhance the effects of other anticancer agents, making it a candidate for combination therapies. Its unique mechanism of action—targeting PH domains rather than kinase activity—offers a novel approach to overcoming resistance seen with traditional kinase inhibitors. Research remains largely in the preclinical stage, but it holds promise as a targeted therapeutic agent in oncology.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :